{
  "run_id": "RUN_20260204_234342_996d5a3920e1",
  "timestamp": "2026-02-05T05:51:00.533350",
  "document": "Giant-Cell-Arteritis.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/train/Giant-Cell-Arteritis.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 2,
  "total_validated": 2,
  "total_rejected": 0,
  "total_investigational": 2,
  "drugs": [
    {
      "matched_text": "steroids",
      "preferred_name": "Steroids",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "NOT_YET_RECRUITING",
      "sponsor": null,
      "conditions": [
        "Vestibular Schwannoma",
        "Facial Nerve Paralysis"
      ],
      "nct_id": "NCT07116811",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "D013256",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT07116811",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D013256",
          "display": "Steroids"
        }
      ],
      "context": "of patients with giant call arteritis. 15% to 20% of persons with polymyalgia rheumatica will have giant cell arteritis. Treatments available include steroids (corticosteroids) that will help with symptoms and reoccurrence and medications that weaken the immune system. Giant cell arteritis most commonly aff",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Phytosterols",
        "Cardiac Glycosides",
        "Steroids Fluorinated"
      ],
      "pubtator_normalized_name": "Steroids",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "corticosteroids",
      "preferred_name": "corticosteroids",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "NOT_YET_RECRUITING",
      "sponsor": null,
      "conditions": [
        "Ocular Myasthenia Gravis"
      ],
      "nct_id": "NCT06342544",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C011244",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT06342544",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C011244",
          "display": "corticosteroid methanetriol mixture"
        }
      ],
      "context": "s with giant call arteritis. 15% to 20% of persons with polymyalgia rheumatica will have giant cell arteritis. Treatments available include steroids (corticosteroids) that will help with symptoms and reoccurrence and medications that weaken the immune system. Giant cell arteritis most commonly affects those over 5",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "corticosteroid methanetriol mixture",
      "enrichment_source": "pubtator3"
    }
  ]
}